^
Association details:
| Biomarker: | FGF19 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | H3B-6527 (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Excerpt:
...the 40 HCC cell line panel and 30 HCC PDX models demonstrate that FGF19 overexpression is a predictive biomarker for H3B-6527 response and evaluation of 231 primary HCC samples suggest approximately 20% of HCC patients may potentially benefit from H3B-6527 treatment.
DOI:
10.1158/0008-5472.CAN-17-1865
